There was not a significant difference in the overall two-year survival time -- 30.5 months for the gefitinib group compared with 23.6 months in the chemotherapy group. However, the progression-free survival time and safety profile were significantly better in the gefitinib group, researchers found. 在超过两年的存活期的两组直接并没有非常明显的区别-吉非替尼组30.6个月，化疗组23.6个月。但是，研究人员发现，无癌症进展生存时间和安全性两个方面吉非替尼组要明显好于化疗组。
Chemotherapy patients were also significantly more likely to suffer severe toxic effects, including anemia and nerve damage, from their treatment than were those taking gefitinib (71.7 percent vs. 41.2 percent). 相对于服用吉非替尼的病人来说，化疗病人也明显更可能遭受严重毒性包括贫血和神经损伤。（71.7%41.2%）。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
